You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of patients at baseline

From: Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study

Characteristic Baseline values (n = 32)
Sex  
Male 17 (53.1%)
Female 15 (46.9%)
ECOG performance status  
0 17 (53.1%)
1 15 (46.9%)
Mean age (range) - years 65.4 (20–85)
M-stage  
M1a 4 (12.5%)
M1b 4 (12.5%)
M1c 24 (75.0%)
Visceral metastases 28 (87.5%)
Non visceral metastases 4 (12.5%)
LDH level  
</=Upper limit of the normal range 18 (56.3%)
> Upper limit of the normal range 14 (43.8%)
Number of previous therapies  
1 17 (53.1%)
2 7 (21.9%)
3 4 (12.5%)
≥4 4 (12.5%)
Previous anticancer treatment  
Chemotherapy* 29 (90.6%)
Immunotherapy** 12 (37.5%)
Other anticancer therapy*** 8 (25.0%)
  1. Data are number (%) or mean. *Carboplatin, Cisplatin, DTIC, Fotemustine, Gemcitabine, Melphalan, Paclitaxel, Treosulfan, Vindesine, **IFN, Ipilimumab, Thymosin, ***CNTO, Genasense, Imatinib, Sorafenib, STA-4783-08.